Literature DB >> 15219500

Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction.

Marc J Claeys1, Johan Bosmans, Michel De Ceuninck, Anthony Beunis, Wim Vergauwen, Anne Vorlat, Chris J Vrints.   

Abstract

Despite early recanalization of an occluded infarct artery, up to 33% of patients with acute myocardial infarction do not obtain complete myocardial reperfusion due to a process of reperfusion injury. This study assessed whether adjunctive therapy with adenosine might prevent or attenuate the phenomenon of myocardial reperfusion injury. Myocardial reperfusion was assessed in 79 consecutive patients receiving a 20-minute intracoronary infusion of adenosine during percutaneous coronary intervention (PCI) and in a historical cohort of 200 patients with acute myocardial infarction who were treated with PCI (controls). Myocardial reperfusion injury was defined as persistent (> or =50% of initial value) ST-segment elevation after successful recanalization. Its effect on infarct size was evaluated by calculating the Selvester QRS score before intervention and at follow-up. Myocardial reperfusion injury was present in 19% of patients receiving adenosine versus 35% of control patients (p = 0.004). Evaluation of infarct expansion over time showed almost no change in the QRS score in patients receiving adenosine (3.4 +/- 3.0 before PCI; 3.5 +/- 3.1 at follow-up). In contrast, infarct QRS score in the control group worsened from 3.1 +/- 2.7 before PCI to 4.5 +/- 3.2 at follow-up (p = 0.003 treatment with adenosine vs control). Multivariate analysis identified adjunctive therapy with adenosine as an independent protective determinant of myocardial reperfusion injury and of infarct expansion. The rate of major adverse cardiac events (death and myocardial infarction) at 1 month tended to be lower in patients receiving adenosine (4% vs 6.5%, p = 0.7) and was mainly observed in patients with evidence of myocardial reperfusion injury (cardiac event rate 2% in patients with ST-segment elevation of <50% vs 14% in patients with ST-segment elevation > or =50%, p = 0.003). Thus, impaired myocardial reperfusion is the most important determinant of clinical outcome in patients with acute myocardial infarction treated with PCI. Adjunctive therapy with intracoronary infusion of adenosine during PCI prevents the occurrence of severe myocardial reperfusion injury and is associated with less infarct expansion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219500     DOI: 10.1016/j.amjcard.2004.03.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention.

Authors:  Bilian Zhao; Jian Li; Xinping Luo; Qing Zhou; Hua Chen; Haiming Shi
Journal:  Tex Heart Inst J       Date:  2011

2.  Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice.

Authors:  Maryam Sharifi Sanjani; Bunyen Teng; Thomas Krahn; Stephen Tilley; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

Review 3.  Role of Sam68 as an adaptor protein in signal transduction.

Authors:  S Najib; C Martín-Romero; C González-Yanes; V Sánchez-Margalet
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

4.  Serum NT-proBNP on admission can predict ST-segment resolution in patients with acute myocardial infarction after primary percutaneous coronary intervention.

Authors:  Bin Peng; Hao Xia; Aihua Ni; Gang Wu; Xuejun Jiang
Journal:  Herz       Date:  2015-05-22       Impact factor: 1.443

5.  Evaluation of Short- and Long-Term Efficacy of Combined Intracoronary Administration of High-Dose Adenosine and Tirofiban during Primary Percutaneous Coronary Intervention.

Authors:  Yanbing Li; Qiang Li; Feiou Li; Min Zong; Guobin Miao; Xinchun Yang; Zichuan Tong; Jianjun Zhang
Journal:  Acta Cardiol Sin       Date:  2016-11       Impact factor: 2.672

6.  Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury.

Authors:  Katrina Go Yamazaki; Diego Romero-Perez; Maraliz Barraza-Hidalgo; Michelle Cruz; Maria Rivas; Brenda Cortez-Gomez; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

7.  Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow.

Authors:  Mohammad-Reza Movahed; Gurpreet Baweja
Journal:  Exp Clin Cardiol       Date:  2008

8.  Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention.

Authors:  Hua Zhou; Xiao-Yan He; Shao-Wei Zhuang; Juan Wang; Yan Lai; Wei-Gang Qi; Yi-An Yao; Xue-Bo Liu
Journal:  World J Emerg Med       Date:  2014

9.  Comparison of the effects of adenosine, inosine, and their combination as an adjunct to reperfusion in the treatment of acute myocardial infarction.

Authors:  Abdel Shafy; Vincent Molinié; Miguel Cortes-Morichetti; Vincent Hupertan; Nermine Lila; Juan C Chachques
Journal:  ISRN Cardiol       Date:  2012-03-14

10.  Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial.

Authors:  Hamid Reza Sanati; Reza Ghanavati; Ali Zahedmehr; Farshad Shakerian; Hooman Bakhshandeh; Ata Firouzi; Reza Kiani
Journal:  J Tehran Heart Cent       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.